We are live on
!
Find out more
PBPIA
Pivotal bioVenture Partners Investment Advisor Portfolio holdings
AUM
$280M
1-Year Est. Return
181.4%
This Fund
S&P 500
This Quarter
Est. Return
-8.19%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$124M
AUM Growth
-$24.5M
(-17%)
Cap. Flow
+$12.1M
Cap. Flow
% of AUM
9.79%
Top 10 Holdings %
Top 10 Hldgs %
99.39%
Holding
11
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oculis Holding
OCS
|
+$11.5M |
| 2 |
Vaxcyte
PCVX
|
+$552K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
HCM
OFCM
NCM
CCC
PHC
VP
SL
CC
Pivotal bioVenture Partners Investment Advisor's Q1 2025 Portfolio in Review
As of Q1 2025, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $124M, down 17% from $148M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Pivotal bioVenture Partners Investment Advisor deployed $12.1M of net new capital in Q1 2025, adding to 2 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Pivotal bioVenture Partners Investment Advisor added most to Oculis Holding in Q1 2025, an estimated $11.5M increase.
- Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $124M portfolio in Q1 2025.
- Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 0 in Q1 2025.
- Pivotal bioVenture Partners Investment Advisor's portfolio value fell 17% quarter-over-quarter to $124M.
Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2025, filed 14 May 2025.